Cor Vasa 2024, 66(5):518-524 | DOI: 10.33678/cor.2024.051

Cardiovascular Risk Assessment in Chronic Obstructive Pulmonary Disease Patients

Anastasiia Melenevycha, Olga Melenevychb
a Department of Internal and Occupational Diseases, Kharkiv National Medical University, Kharkiv, Ukraine
b Therapeutic Department, Municipal Non-Commercial Enterprise "City Polyclinic № 5" of Kharkiv City Council, Kharkiv, Ukraine

Prevention of adverse cardiovascular (CV) events is a challenging part of managing patients with chronic obstructive pulmonary disease (COPD). Common pathophysiological mechanisms are a prerequisite for the mutual burden of comorbid pathology, COPD, and cardiovascular diseases (CVD). Controversies in the assessment of traditional CV risk factors, untimely detection of existing CVD, heterogeneity of the course of COPD, and the influence of COPD medications on CV risk - all these indicate the need for additional clarifications regarding the assessment of CV risk in patients with COPD. This review summarizes recent studies on CV risk assessment in patients with COPD and suggests approaches to improve the prediction of adverse CV events in these patients.

Keywords: Cardiovascular risk, Chronic obstructive pulmonary disease, Major adverse cardiovascular events, Risk factors,

Received: May 10, 2024; Revised: May 10, 2024; Accepted: June 24, 2024; Prepublished online: June 2, 2012; Published: October 25, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melenevych A, Melenevych O. Cardiovascular Risk Assessment in Chronic Obstructive Pulmonary Disease Patients. Cor Vasa. 2024;66(5):518-524. doi: 10.33678/cor.2024.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Al Wachami N, Guennouni M, Iderdar Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health 2024;24:297. Go to original source... Go to PubMed...
    2. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022;10:447-458. Go to original source... Go to PubMed...
    3. López-Pardo ME, Candal-Pedreira C, Valdés-Cuadrado L, et al. Factors Related with Hospital Attendance and Mortality in Patients with COPD: A Case-Control Study in a Real-Life Setting. Int J Chron Obstruct Pulmon Dis 2022;17:809-819. Go to original source... Go to PubMed...
    4. Amegadzie JE, Lee TY, Sadatsafavi M, et al. Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada. CMAJ 2023;195:E1172-E1179. Go to original source... Go to PubMed...
    5. Reilev M, Pottegård A, Lykkegaard J, et al. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirology 2019;24:1183-1190. Go to original source... Go to PubMed...
    6. Su X, Gu H, Li F, et al. Global, Regional, and National Burden of COPD Attributable to Occupational Particulate Matter,Gases, and Fumes, 1990-2019: Findings from the Global Burden of Disease Study 2019. Int J Chron Obstruct Pulmon Dis 2023;18:2971-2983. Go to original source... Go to PubMed...
    7. Maclagan LC, Croxford R, Chu A, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J 2023;62:2202364. Go to original source... Go to PubMed...
    8. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2022;29:5-115. Go to original source... Go to PubMed...
    9. Trinkmann F, Saur J, Borggrefe M, Akin I. Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice. J Clin Med 2019;8:69. Go to original source... Go to PubMed...
    10. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol 2017;70:128-134. Go to original source... Go to PubMed...
    11. André S, Conde B, Fragoso E, et al. COPD and Cardiovascular Disease. Pulmonology 2019;25:168-176. Go to original source... Go to PubMed...
    12. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015;3:631-639. Go to original source... Go to PubMed...
    13. Vanfleteren LEGW, Spruit MA, Wouters EFM, Franssen FME. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med 2016;4:911-924. Go to original source... Go to PubMed...
    14. Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med 2018;198:51-57. Go to original source... Go to PubMed...
    15. Rothnie KJ, Connell O, Müllerová H, et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2018;15:935-946. Go to original source... Go to PubMed...
    16. Duong M, Islam S, Rangarajan S, et al. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. Lancet Glob Health 2019;7:e613-e623. Go to original source... Go to PubMed...
    17. Triest FJ, Singh SJ, Vanfleteren LE. Cardiovascular risk, chronic obstructive pulmonary disease and pulmonary rehabilitation: Can we learn from cardiac rehabilitation?. Chron Respir Dis 2016;13:286-294. Go to original source... Go to PubMed...
    18. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1835-1878. Go to original source... Go to PubMed...
    19. Axson EL, Ragutheeswaran K, Sundaram V, et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res 2020;21:54. Go to original source... Go to PubMed...
    20. Venkatesan P. GOLD COPD report: 2024 update. Lancet Respir Med 2024;12:15-16. Go to original source... Go to PubMed...
    21. Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021;204:1251-1258. Go to original source... Go to PubMed...
    22. Hughes R, Rapsomaniki E, Janson C, et al. Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir Med 2022;200:106921. Go to original source... Go to PubMed...
    23. Watz H, Tetzlaff K, Magnussen H, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res 2018;19:251. Go to original source... Go to PubMed...
    24. Daniels K, Lanes S, Tave A, et al. Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study. Int J Chron Obstruct Pulmon Dis 2024;19:225-241. Go to original source... Go to PubMed...
    25. Kyriakopoulos C, Gogali A, Kostikas K, Konstantinidis A. Hypercoagulable State in COPD-A Comprehensive Literature Review. Diagnostics (Basel) 2021;11:1447. Go to original source... Go to PubMed...
    26. Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA 2021;325:59-68. Go to original source... Go to PubMed...
    27. Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res 2014;15:89. Go to original source... Go to PubMed...
    28. Wan ES. The Clinical Spectrum of PRISm. Am J Respir Crit Care Med 2022;206:524-525. Go to original source... Go to PubMed...
    29. Wan ES, Balte P, Schwartz JE, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults JAMA 2021;326:2287-2298. Erratum in: JAMA 2022;327:286.
    30. Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J 2020;55:1901217. Go to original source... Go to PubMed...
    31. McDonnell MJ, Ward C, Rutherford RM. Comorbidities and their impact. In: Chalmers JD, Polverino E, Aliberti S, eds. Bronchiectasis (ERS Monograph). Sheffield, European Respiratory Society, 2018:45-61. Go to original source...
    32. Navaratnam V, Millett ER, Hurst JR, et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax 2017;72:161-166. Go to original source... Go to PubMed...
    33. Saleh AD, Kwok B, Brown JS, Hurst JR. Correlates and assessment of excess cardiovascular risk in bronchiectasis. Eur Respir J 2017;50:1701127. Go to original source... Go to PubMed...
    34. Chen YF, Lin HH, Lin CS, et al. Bronchiectasis and increased risk of ischemic stroke: a nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis 2017;12:1375-1383. Go to original source... Go to PubMed...
    35. Marsland I, Sobala R, De Soyza A, Witham M. Multimorbidity in bronchiectasis: a systematic scoping review. ERJ Open Res 2023;9:00296-2022. Go to original source... Go to PubMed...
    36. Mirza S, Benzo R. Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care. Mayo Clin Proc 2017;92:1104-1112. Go to original source... Go to PubMed...
    37. Camiciottoli G, Bigazzi F, Magni C, et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2016;11:2229-2236. Go to original source... Go to PubMed...
    38. Shah AJ, Quek E, Alqahtani JS, et al. Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: A systematic review and meta-analysis. Sleep Med Rev 2022;63:101627. Go to original source... Go to PubMed...
    39. Tang M, Long Y, Liu S, et al. Prevalence of Cardiovascular Events and Their Risk Factors in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Overlap Syndrome. Front Cardiovasc Med 2021;8:694806. Go to original source... Go to PubMed...
    40. Sterling KL, Pépin JL, Linde-Zwirble W, et al. Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2022;206:197-205. Go to original source... Go to PubMed...
    41. Nikolaou V, Massaro S, Garn W, et al. The cardiovascular phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying machine learning to the prediction of cardiovascular comorbidities. Respir Med 2021;186:106528. Go to original source... Go to PubMed...
    42. Brigham EP, Anderson JA, Brook RD, et al. Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. ERJ Open Res 2021;7:00902-2020. Go to original source... Go to PubMed...
    43. Leem AY, Kim YS, Chung KS, et al. Sarcopenia is associated with cardiovascular risk in men with COPD, independent of adiposity. Respir Res 2022;23:185. Go to original source... Go to PubMed...
    44. Giri Ravindran S, Saha D, Iqbal I, et al. The Obesity Paradox in Chronic Heart Disease and Chronic Obstructive Pulmonary Disease. Cureus 2022;14:e25674. Go to original source... Go to PubMed...
    45. Freyberg J, Landt EM, Afzal S, et al. Low-density lipoprotein cholesterol and risk of COPD: Copenhagen General Population Study. ERJ Open Res 2023;9:00496-2022. Go to original source... Go to PubMed...
    46. Schenk P, Spiel AO, Hüttinger F, et al. Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study. Eur Respir J 2021;58:2001798. Go to original source... Go to PubMed...
    47. Waschki B, Alter P, Zeller T, et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. Eur Respir J 2020;55:1901314. Go to original source... Go to PubMed...
    48. Shafuddin E, Fairweather SM, Chang CL, et al. Cardiac biomarkers and long-term outcomes of exacerbations of COPD: a long-term follow-up of two cohorts. ERJ Open Res 2021;7:00531-2020. Go to original source... Go to PubMed...
    49. Nicolae B, Ecaterina L. Natriuretic peptides in elderly patients with chronic obstructive pulmonary disease. Egypt J Bronchol 2022;16:26. Go to original source...
    50. Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med 2021;203:553-564. Go to original source... Go to PubMed...
    51. Prudente R, Ferrari R, Mesquita CB, et al. Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients. Int J Chron Obstruct Pulmon Dis 2021;16:979-985. Go to original source... Go to PubMed...
    52. Liu X, Shi GP, Guo J. Innate Immune Cells in Pressure Overload-Induced Cardiac Hypertrophy and Remodeling. Front Cell Dev Biol 2021;9:659666. Go to original source... Go to PubMed...
    53. Alkhalil M, Kearney A, Hegarty M, et al. Eosinopenia as an Adverse Marker of Clinical Outcomes in Patients Presenting with Acute Myocardial Infarction. Am J Med 2019;132:e827-e834. Go to original source... Go to PubMed...
    54. Tkacz J, Evans KA, Touchette DR, et al. PRIMUS- Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation. Int J Chron Obstruct Pulmon Dis 2022;17:329-342. Go to original source... Go to PubMed...
    55. Regard L, Burgel PR, Roche N. Inhaled therapy, cardiovascular risk and benefit-risk considerations in COPD: innocent until proven guilty, or vice versa?. Eur Respir J 2023;61:2202135. Go to original source... Go to PubMed...
    56. Yang YL, Xiang ZJ, Yang JH, et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2020;41: 4415-4422. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes